US Stem Cell Inc (USRM)

[andyshow]

http://investorstemcell.com/sector/10249/

On dollars and cents, Bioheart has achieved a number of significant financial milestones in 2014. Most importantly, we have increased revenue through international Myocath sales, proprietary stem cell culturing, laboratory kits, as well as physician training throughout the world. Below is a brief summary of financial spotlights:

· – our YTD Revenue increased from $56,000 to $1.6m, 2013 vs. 2014.

· – 3Q Revenue up from $32,000 to $580,000, 2013 vs. 2014.

· – Current liabilities were reduced 23% from $13.4m to $10.3m YTD. This was accomplished by debt to equity conversion at $0.04 as well as debt limitations under Florida law.

· – Working capital deficit improved by 24% from $13.4m to $10m YTD

· – YTD net actual loss down 48% from $2.4m to $1.2m year-over-year.

· – Launched joint ventures in South Africa, Australia, Honduras, Azerbaijan and Columbia.

· – Cash used in operating activities down 52%: $747,000 in YTD 2014 as compared to $1.6m in YTD 2013.

· – $3 million Equity Enhancement Program (“EEP”) with a Magna affiliate fund, Magna Equities II, LLC.

Please view the most recent 10Q here. http://www.bioheartinc.com/Investors/SECFilings

- See more at: http://investorstemcell.com/sector/10249/#sthash.nwz9UTBT.dpuf